The present study assessed whether cranberry supplementation influences liver enzyme activity, hepatic fat content, and cardiometabolic risk parameters in patients diagnosed with non-alcoholic fatty liver disease (NAFLD). This randomized, parallel-group clinical trial included 110 individuals diagnosed with NAFLD, who were assigned to either a 144 mg cranberry supplement or a placebo for a duration of six months. The study primarily evaluated effects on liver enzymes, glycemic control, and lipid metabolism. The trial involved 46 participants receiving the supplement and 48 receiving placebo. Participants had an average age of 43.16 years (SD 11.08). Post-treatment liver enzyme levels showed no notable differences between the two groups. In contrast, the supplementation group exhibited significantly reduced average levels of total cholesterol (p < 0.001) and triglycerides (p = 0.01) compared to the placebo group. At study completion, average insulin concentrations and HOMA-IR values were also markedly lower in the group receiving cranberry supplementation than in the placebo group. Furthermore, a significantly higher number of participants in the cranberry group achieved an improvement in liver steatosis grade relative to the control group. The findings of this study indicate that cranberry supplementation may improve certain lipid parameters, reduce insulin resistance, and positively influence hepatic steatosis in patients with NAFLD.
